Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8422)
All Articles published online
|
Publishing Process of This Article
|
Apr 7, 2017 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Endo D, Satoh K, Shimada N, Hokari A, Aizawa Y. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b. World J Gastroenterol 2017; 23(13): 2355-2364 [PMID: 28428715 DOI: 10.3748/wjg.v23.i13.2355] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i13/2355.htm |
| Number | Citing Articles |
| 1 |
Anca Trifan, Tudor Cuciureanu, Robert Nastasa, Ermina Stratina, Sebastian Zenovia, Cristina Maria Muzica, Laura Huiban, Ana-Maria Singeap, Stefan Chiriac, Catalin Sfarti, Camelia Cojocariu, Irina Girleanu, Horia Minea, Remus Stafie, Adrian Rotaru, Carol Stanciu. Changes in Components of Metabolic Syndrome after Antiviral Eradication in Hepatitis C Virus Infection. Life 2023; 13(2): 534 doi: 10.3390/life13020534
|
| 2 |
Hussein A. AbdEl-maksoud, Mohamed G. Elharrif, Omnia Abd El-hamid, Saad M. Alsaab, Eman M. El-sorady. Monitoring of iron, lipid and liver profiles in Egyptian hepatitis C virus patients on sofosbuvir therapy. Journal of Infection and Public Health 2022; 15(3): 277 doi: 10.1016/j.jiph.2022.01.008
|
| 3 |
Jonathan Grimm, Georg Peschel, Martina Müller, Doris Schacherer, Reiner Wiest, Kilian Weigand, Christa Buechler. Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy. Journal of Clinical Medicine 2021; 10(8): 1621 doi: 10.3390/jcm10081621
|
| 4 |
Ayush Jain, Bhupinder Singh Kalra, Siddharth Srivastava, Shalini Chawla. Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients. Indian Journal of Gastroenterology 2019; 38(1): 39 doi: 10.1007/s12664-019-00935-w
|
| 5 |
Martina Spaziante, Gloria Taliani, Giulia Marchetti, Alessandro Tavelli, Miriam Lichtner, Antonella Cingolani, Stefania Cicalini, Elisa Biliotti, Enrico Girardi, Andrea Antinori, Massimo Puoti, Antonella d’Arminio Monforte, Alessandro Cozzi-Lepri. Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study. Viruses 2021; 13(7): 1402 doi: 10.3390/v13071402
|
| 6 |
Tingting Mei, Xiaojie Huang, Shan Tang, Menglu Liu, Wenyan Zhang, Haibin Yu. Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis. Lipids in Health and Disease 2024; 23(1) doi: 10.1186/s12944-023-01957-2
|
| 7 |
Kilian Weigand, Georg Peschel, Jonathan Grimm, Martina Müller, Marcus Höring, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler. HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV. Biomedicines 2022; 10(12): 3152 doi: 10.3390/biomedicines10123152
|
| 8 |
Marta Hernández‐Conde, Inmaculada Fernández, Christie Perelló, Adolfo Gallego, Martin Bonacci, Juan M. Pascasio, Manuel Romero‐Gómez, Susana Llerena, Conrado Fernández‐Rodríguez, José L. Castro Urda, Luisa García Buey, Isabel Carmona, Rosa M. Morillas, Nuria Domínguez García, Francisco Gea, José A. Carrión, Jose Castellote, Jose M. Moreno‐Planas, Belén Piqueras Alcol, Esther Molina, Moises Diago, Silvia Montoliu, Juan de la Vega, Fernando Menéndez, Juan J. Sánchez Ruano, Javier García‐Samaniego, Jose M. Rosales‐Zabal, María D. Anton, Ester Badia, Raquel Souto‐Rodríguez, Francisco J. Salmeron, Miguel Fernández‐Bermejo, Blanca Figueruela, Jose J. Moreno‐Palomares, Jose L. Calleja. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA‐C real‐world cohort. Journal of Viral Hepatitis 2019; 26(1): 55 doi: 10.1111/jvh.13008
|
| 9 |
Joana Ferreira, Manuel Bicho, Fátima Serejo. Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters. Viruses 2024; 16(3): 371 doi: 10.3390/v16030371
|
| 10 |
Takako Inoue, Takaaki Goto, Etsuko Iio, Kayoko Matsunami, Kei Fujiwara, Noboru Shinkai, Kentaro Matsuura, Takeshi Matsui, Shunsuke Nojiri, Yasuhito Tanaka. Changes in serum lipid profiles caused by three regimens of interferon‐free direct‐acting antivirals for patients infected with hepatitis C virus. Hepatology Research 2018; 48(3) doi: 10.1111/hepr.12970
|
| 11 |
Vanessa Gutierrez de ANDRADE, Fabio da Silva YAMASHIRO, Cassio Vieira OLIVEIRA, Leticia Lastória KUROZAWA, Alecsandro MOREIRA, Giovanni Faria SILVA. INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION?. Arquivos de Gastroenterologia 2018; 55(2): 184 doi: 10.1590/s0004-2803.201800000-33
|
| 12 |
Moris Sangineto, Chiara Valentina Luglio, Tommaso Mastrofilippo, Maria Teresa Zingaro, Elsa Berardi, Gianfranco Antonica, Carlo Sabbà, Nicola Napoli. Analysis of hepatic stiffness after viral eradication in a population with chronic hepatitis C treated with DAAs. Medicina Clínica (English Edition) 2021; 156(7): 317 doi: 10.1016/j.medcle.2020.04.035
|
| 13 |
Elena González-Colominas, Marc Batlle, Inés Monge-Escartín, Xavier Duran, Anna Viu, Marta de Antonio-Cuscó, Santiago Grau, Xavier Bessa, Jose Antonio Carrión. Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response. European Journal of Gastroenterology & Hepatology 2021; 32(2): 214 doi: 10.1097/MEG.0000000000001714
|
| 14 |
Pin-Nan Cheng, Hung-Yu Sun, I-Che Feng, Yen-Cheng Chiu, Sin-Tian Wang, Dyoness Charmaine Tan, Hung-Chih Chiu, Shih-Chih Chien, Kung-Chia Young. Interdependence of glycemic and lipid modulation in cured chronic hepatitis C patients by direct-acting antiviral agents. Journal of Microbiology, Immunology and Infection 2023; 56(1): 20 doi: 10.1016/j.jmii.2022.06.004
|
| 15 |
Nageh Ahmed El-Mahdy, Sabry Abou-Saif, Medhat Ismail Abd EL hamid, Heba M. Hashem, Mohamed Anwar Hammad, Sally El-Sayed Abu-Risha. Evaluation of the effect of direct-acting antiviral agents on melatonin level and lipid peroxidation in chronic hepatitis C patients. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1128016
|
| 16 |
Anca Trifan, Ermina Stratina, Adrian Rotaru, Remus Stafie, Sebastian Zenovia, Robert Nastasa, Laura Huiban, Catalin Sfarti, Camelia Cojocariu, Tudor Cuciureanu, Cristina Muzica, Stefan Chiriac, Irina Girleanu, Ana-Maria Singeap, Carol Stanciu. Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response. Diagnostics 2022; 12(3): 702 doi: 10.3390/diagnostics12030702
|
| 17 |
Georg Peschel, Sabrina Krautbauer, Kilian Weigand, Jonathan Grimm, Marcus Höring, Gerhard Liebisch, Martina Müller, Christa Buechler. Rising Lysophosphatidylcholine Levels Post-Hepatitis C Clearance. International Journal of Molecular Sciences 2024; 25(2): 1198 doi: 10.3390/ijms25021198
|
| 18 |
Noriyuki Akutsu, Shigeru Sasaki, Takeshi Matsui, Hirofumi Akashi, Kazuhiko Yonezawa, Keisuke Ishigami, Masayuki Tsujisaki, Hiroyuki Isshiki, Atsushi Yawata, Satoshi Yamaoka, Toshihiro Ban, Takeya Adachi, Seiya Nakahara, Hideyasu Takagi, Kohei Nakachi, Katsunori Tanaka, Takehiro Hirano, Itaru Yamamoto, Hiroyuki Kaneto, Kohei Wagatsuma, Yasunao Numata, Hiroshi Nakase. Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment. Internal Medicine 2021; 60(21): 3369 doi: 10.2169/internalmedicine.7098-21
|
| 19 |
Kilian Weigand, Georg Peschel, Jonathan Grimm, Marcus Höring, Sabrina Krautbauer, Gerhard Liebisch, Martina Müller, Christa Buechler. Serum Phosphatidylcholine Species 32:0 as a Biomarker for Liver Cirrhosis Pre- and Post-Hepatitis C Virus Clearance. International Journal of Molecular Sciences 2024; 25(15): 8161 doi: 10.3390/ijms25158161
|
| 20 |
Mahmoud Abdo, Ahmed Rabiee, Zeinab Abdellatif, Shereen Abdel Alem, Ahmed Moustafa. Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir. European Journal of Gastroenterology & Hepatology 2021; 33(12): 1588 doi: 10.1097/MEG.0000000000001903
|
| 21 |
Rui Hua, Fei Kong, Guangming Li, Xiaofeng Wen, Yuexin Zhang, Xingxiang Yang, Chenxin Meng, Wen Xie, Yongfang Jiang, Xiaozhong Wang, Xueji Han, Yan Huang, Qing Mao, Jiefei Wang, Yujuan Guan, Jiayu Chen, Yingjie Ma, Qingfang Xiong, Hong Ma, Xuebing Yan, Huiying Rao, Yingren Zhao, Tong Sun, Liying Zhu, Xiaorong Mao, Jianqi Lian, Guojiong Deng, Yongning Xin, Yifei Wang, Yinong Ye, Bin Xu, Hainv Gao, Youwen Tan, Dongliang Li, Dongliang Yang, Minghua Su, Xiaomeng Zhang, Jie Min, Xinsheng Shi, Lai Wei, Junqi Niu. Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China. Infectious Diseases and Therapy 2023; 12(11): 2595 doi: 10.1007/s40121-023-00872-4
|
| 22 |
Andrea Pascual-Oliver, Diego Casas-Deza, Carmen Yagüe-Caballero, Jose M. Arbones-Mainar, Vanesa Bernal-Monterde. Lipid Profile and Cardiovascular Risk Modification after Hepatitis C Virus Eradication. Pathogens 2024; 13(4): 278 doi: 10.3390/pathogens13040278
|
| 23 |
Tatsuki Ichikawa, Hisamitsu Miyaaki, Satoshi Miuma, Yasuhide Motoyoshi, Syouhei Narita, Satomi Toda, Youichi Takahashi, Tetsurou Honda, Hiroyuki Yajima, Ryouhei Uehara, Naoyuki Hino, Tomoko Hori, Ryousuke Hirata, Naota Taura, Kazuhiko Nakao. Carotid Intima-media Thickness and Small Dense Low-density Lipoprotein Cholesterol Increase after One Year of Treatment with Direct-acting Antivirals in Patients with Hepatitis C Virus Infection. Internal Medicine 2019; 58(9): 1209 doi: 10.2169/internalmedicine.1514-18
|
| 24 |
Antonio Rivero-Juarez, Angela Camacho, Teresa Brieva, Mario Frias, Pedro Lopez-Lopez, María A. Risalde, Isabel Machuca, Juan J. Caston, Antonio Martínez-Peinado, Antonio Rivero. Brief Report: Differential Timing of Cholesterol Increase During Successful HCV Therapy: Impact of Type of Drug Combination. JAIDS Journal of Acquired Immune Deficiency Syndromes 2018; 78(4): 437 doi: 10.1097/QAI.0000000000001691
|
| 25 |
Kohei Shimizu, Yoko Soroida, Masaya Sato, Hiromi Hikita, Tamaki Kobayashi, Momoe Endo, Mamiko Sato, Hiroaki Gotoh, Tomomi Iwai, Ryosuke Tateishi, Kazuhiko Koike, Yutaka Yatomi, Hitoshi Ikeda. Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-26293-9
|
| 26 |
Ying-Wen Wang, Wei-Ping Lee, Yi-Hsiang Huang, Ming-Chih Hou, Keng-Hsin Lan. Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis. BMC Infectious Diseases 2021; 21(1) doi: 10.1186/s12879-021-06657-9
|
| 27 |
Moris Sangineto, Chiara Valentina Luglio, Tommaso Mastrofilippo, Maria Teresa Zingaro, Elsa Berardi, Gianfranco Antonica, Carlo Sabbà, Nicola Napoli. Analysis of hepatic stiffness after viral eradication in a population with chronic hepatitis C treated with DAAs. Medicina Clínica 2021; 156(7): 317 doi: 10.1016/j.medcli.2020.04.050
|
| 28 |
Ahmed Samir Allam, Mohamed Lotfy Abd Elmeged, Sameh Mohamed Ghaly, Osama Ashraf Ahmed, Gina Gamal Naguib, Ahmed Samir Abohalima. Impact of direct-acting antiviral therapy on metabolic profiles and adiponectin serum level in different categories of patients with chronic hepatitis C infection. Egyptian Liver Journal 2022; 12(1) doi: 10.1186/s43066-022-00194-z
|
| 29 |
Phuong Nguyen Thi Thu, Dung Hoang Van, Mai Ngo Thi Quynh, Ngan Tran Thi, Khue Pham Minh, Linh Pham Van, Tyng-Yuan Jang. Metabolic, renal, and hematological changes in chronic hepatitis C patients achieving rapid virologic response after 12 weeks of direct-acting antiviral treatment: A prospective cohort study. PLOS ONE 2023; 18(9): e0290235 doi: 10.1371/journal.pone.0290235
|
| 30 |
Nehal K. Abdel Fattah, Sara M. Shaheen, Osama A. Ahmed, Kadry Elsaeed, Nagwa A. Sabri. Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals. F1000Research 2022; 11: 649 doi: 10.12688/f1000research.109397.1
|
| 31 |
Diego Casas-Deza, Ana Martínez-Sapiña, Silvia Espina, Beatriz Garcia-Rodriguez, Eva M. Fernandez-Bonilla, Alejandro Sanz-Paris, Yolanda Gonzalez-Irazabal, Vanesa Bernal-Monterde, Jose M. Arbones-Mainar. Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Naïve Patients without History of Cardiovascular Disease. Journal of Clinical Medicine 2022; 11(14): 4049 doi: 10.3390/jcm11144049
|
| 32 |
Annalisa Cespiati, Inês Coelho Rodrigues, Inês Santos, Sara Policarpo, Sofia Carvalhana, Anna Ludovica Fracanzani, Helena Cortez‐Pinto. Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review. Liver International 2024; 44(5): 1075 doi: 10.1111/liv.15876
|
| 33 |
Tatsuo Kanda, Mitsuhiko Moriyama. Direct-acting antiviral agents against hepatitis C virus and lipid metabolism. World Journal of Gastroenterology 2017; 23(31): 5645-5649 doi: 10.3748/wjg.v23.i31.5645
|
| 34 |
Daisuke Morihara, Yi‐Ling Ko, Kumiko Shibata, Ryo Yamauchi, Hiromi Fukuda, Naoaki Tsuchiya, Atsushi Fukunaga, Hideo Kunimoto, Hideyuki Iwashita, Kazuhide Takata, Takashi Tanaka, Kunitoshi Sakurai, Shinjiro Inomata, Keiji Yokoyama, Shinya Nishizawa, Yasuaki Takeyama, Makoto Irie, Satoshi Shakado, Tetsuro Sohda, Shotaro Sakisaka. IL28B gene polymorphism is correlated with changes in low‐density lipoprotein cholesterol levels after clearance of hepatitis C virus using direct‐acting antiviral treatment. Journal of Gastroenterology and Hepatology 2019; 34(11): 2019 doi: 10.1111/jgh.14741
|
| 35 |
Ghada El Sagheer, Elwy Soliman, Asmaa Ahmad, Lamiaa Hamdy. Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs. Libyan Journal of Medicine 2018; 13(1): 1435124 doi: 10.1080/19932820.2018.1435124
|
| 36 |
Rosanna Villani, Francesca Di Cosimo, Antonino Davide Romano, Moris Sangineto, Gaetano Serviddio. Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-93251-3
|
| 37 |
Rui Hua, Fei Kong, Xiaofeng Wen, Qingfang Xiong, Jiayu Chen, Chenxin Meng, Hong Ma, Youwen Tan, Yan Huang, Yongfang Jiang, Yujuan Guan, Xiaorong Mao, Jiefei Wang, Yongning Xin, Hainv Gao, Bin Xu, Cheng Li, Qiong Wu, Xian Zhang, Zhiqiang Wang, Liwen Zhao, Yuexin Zhang, Guangming Li, Junqi Niu. Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open‐label, phase 2 study. Journal of Viral Hepatitis 2022; 29(6): 455 doi: 10.1111/jvh.13650
|
| 38 |
Cheng‐Heng Lin, Jyh‐Jou Chen, Pei‐Lun Lee, Hung‐Da Tung, Chun‐Ta Cheng, Hsu‐Ju Kao, Yu‐Hsun Wu, Mai‐Gio Pang, Tang‐Wei Chuang. Lipid profile changes after direct acting antiviral treatment in different genotypes of chronic hepatitis C virus‐infected patients. Advances in Digestive Medicine 2021; 8(3): 139 doi: 10.1002/aid2.13211
|
| 39 |
Anna Maria Spera, Valeria Conti, Graziamaria Corbi, Tiziana Ascione, Michele Ciccarelli, Alfonso Masullo, Gianluigi Franci, Pasquale Pagliano. Changes in the Lipid Asset of HIV/HCV Patients after a Successful Course of Direct-Acting Antivirals. Journal of Clinical Medicine 2024; 13(13): 3865 doi: 10.3390/jcm13133865
|
| 40 |
Sylvia Drazilova, Jakub Gazda, Martin Janicko, Peter Jarcuska. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Canadian Journal of Gastroenterology and Hepatology 2018; 2018: 1 doi: 10.1155/2018/6150861
|
| 41 |
Naoyuki Hino, Ryu Sasaki, Youichi Takahashi, Makiko Koike, Masanori Fukushima, Masafumi Haraguchi, Takuya Honda, Satoshi Miuma, Eisuke Ozawa, Hisamitsu Miyaaki, Tatsuki Ichikawa, Kazuhiko Nakao. Treatment of Hepatitis C Virus Infection with Direct-acting Antiviral Agents Elevates the Serum Small-dense Low-density Lipoprotein Cholesterol Level. Internal Medicine 2021; 60(2): 191 doi: 10.2169/internalmedicine.5563-20
|